3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Stomach Neoplasms
3
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Liver Neoplasms
2
Hepatoblastoma
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Wilms Tumor
1
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Penile Neoplasms
1
Ototoxicity
1
Neuroblastoma
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Interventions
fludarabine
3
Vaccines
3
Radiotherapy
3
Papillomavirus Vaccines
3
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
entinostat
2
aldesleukin
2
aflibercept
2
Trastuzumab
2
Surveys and Questionnaires
2
Specimen Handling
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
durvalumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Vorinostat
×
Gastrointestinal
×
Clear all
NCT04357873
2025-02-19
PEVOsq
UNICANCER
Phase 2
Completed
112 enrolled